Pfizer (NYSE: PFE) is currently facing investor skepticism due to upcoming patent expirations for three key drugs in 2027 and 2028, with no clear revenue replacements on the horizon. As one of the largest pharmaceutical companies, Pfizer operates in a highly competitive and regulated industry that relies heavily on research and development. Despite the negative sentiment, there may be opportunities to buy the dip as the market reacts to these challenges. Investors are encouraged to look beyond the current fears and consider Pfizer’s long-term potential.
